Business
Full Year Results Investor Presentation
Full Year Results Investor Presentation.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8441B\n Sareum Holdings PLC\n 13 October 2020\n \n \n \n \n Sareum Holdings PLC \n \n \n (\"Sareum\" or the \"Company\") \n \n INVESTOR PRESENTATION\n \n Cambridge, UK, 13 October 2020 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce that, further to today's Final Results announcement, Dr Tim Mitchell will deliver a live online presentation to investors via the Investor Meet Company (\"IMC\") platform at 10.00 a.m. on Friday, 16 October 2020.\n Existing and potential investors wishing to participate in the presentation should register with IMC at: www.investormeetcompany.com/sareum-holdings-plc/register-investor. Investors who have already registered with IMC and requested to meet the Company will be invited automatically.\n Questions can be submitted before the event via the IMC dashboard or at any time during the live presentation via the \"Ask a Question\" function. Although the Company may not be able to answer every question it receives, it will seek to address the most prominent questions within the confines of information already disclosed to the market. Responses from the Q&A session will be published at the earliest opportunity on the IMC platform.\n A copy of the presentation will be made available on the Company's website following the presentation.\n For further information, please contact: \n \n Sareum Holdings plc\n \n \n Tim Mitchell, CEO 01223 497 700\n \n \n Strand Hanson Limited (Nominated Adviser)\n \n \n James Dance / Richard Tulloch 020 7409 3494\n \n \n Hybridan LLP (Nominated Broker)\n \n \n Claire Noyce / John Beresford-Peirse 020 3764 2341\n \n \n Citigate Dewe Rogerson (Financial PR)\n \n \n Mark Swallow/ David Dible 020 7638 9571\n \n About Sareum\n Sareum is a specialist drug development company delivering targeted small m...